THOUSAND OAKS, Calif., Sept. 24, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering…
FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
Share this article
More News
Analysts reset Broadcom stock price target
May 21, 2026
Lumentum Stock Analysis: Buy or Sell?
May 21, 2026